Editas Medicine, Inc. Stockholders Equity

• Editas Medicine, Inc. showed a decrease of -79.7% in Stockholders Equity from 2024 to 2025.
• This data is from Editas Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: $201.36 million | Q2 2016: $187.33 million | Q3 2016: $170.18 million | Q1 2017: $206.46 million | Q2 2017: $185.00 million | Q3 2017: $177.79 million | Q1 2018: $247.51 million | Q2 2018: $231.33 million | Q3 2018: $224.45 million | Q1 2019: $217.16 million | Q2 2019: $193.06 million | Q3 2019: $209.99 million | Q1 2020: $234.57 million | Q2 2020: $426.77 million | Q3 2020: $441.15 million | Q1 2021: $638.00 million | Q2 2021: $613.36 million | Q3 2021: $586.79 million | Q1 2022: $512.76 million | Q2 2022: $465.41 million | Q3 2022: $414.75 million | Q1 2023: $317.47 million | Q2 2023: $399.92 million | Q3 2023: $360.46 million | Q1 2024: $294.40 million | Q2 2024: $232.01 million | Q3 2024: $175.63 million | Q1 2025: $62.42 million | Q2 2025: $19.19 million | Q3 2025: $13.45 million.
• Over the full 13 years of available data (2013 to 2025), Editas Medicine, Inc.'s Stockholders Equity has grown by 1,647.8%.
• Historical annual values: Fiscal year 2025: $27.29 million | Fiscal year 2024: $134.27 million | Fiscal year 2023: $349.10 million | Fiscal year 2022: $360.68 million | Fiscal year 2021: $553.64 million | Fiscal year 2020: $393.59 million | Fiscal year 2019: $262.44 million | Fiscal year 2018: $236.16 million | Fiscal year 2017: $208.08 million | Fiscal year 2016: $134.61 million | Fiscal year 2015: -$83.11 million | Fiscal year 2014: -$15.29 million | Fiscal year 2013: -$1.76 million.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026